New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

Today's Free Fly Stories
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | all day >>
08:06 EDTKAMNKaman awarded contract extension by Bell Helicopter
Subscribe for More Information
08:06 EDTABAXAbaxis acquires U.K.-based distribution organization
Subscribe for More Information
08:06 EDTIFFInternational Flavors opens new flavors facilities in Indonesia, Chile
International Flavors & Fragrances announced the opening of a creative facility in Jakarta, Indonesia, and a sales office and applications laboratories in Santiago, Chile.
08:05 EDTKWKennedy Wilson acquires 280-unit apartment community for $46.75M
Subscribe for More Information
08:05 EDTABBVCHMP grants positive opinions of VIEKIRAX/EXVIERA combo for Hep C
Subscribe for More Information
08:05 EDTOil Action: NYMEX crude is up to $77.75/bbl
Oil Action: NYMEX crude is up to $77.75/bbl, up from $75.62 lows, on the back of China's rate cut, posting eight-session highs in the process. Adding to the rally has been a shift in sentiment toward an OPEC production cut next week, where members Venezuela and Libya have indicated they are agreeable to reducing output. Initial resistance is seen just under $78, where prices peaked on November 11-12.
08:04 EDTGMANGordmans Stores sees Q4 3c-8c, consensus 9c
Subscribe for More Information
08:04 EDTEXC, POMFERC approves merger of Exelon, Pepco Holdings
Subscribe for More Information
08:03 EDTCYTXCytori Therapeutics announces results in Cytori Cell Therapy trial
Cytori Therapeuticsreported positive results from a clinical study of Cytori Cell Therapy in anterior cruciate ligament reconstruction of patients with ACL tears. The 6 month results from the first 20 patients with combination Cytori Cell Therapy and bone-patellar tendon-bone grafts were presented at the Barcelona Knee Symposium on November 20, 2014. Dr. Ramon Cugat, co-director of the Orthopedic Institute, Hospital Quiron Barcelona and the lead investigator of the study, performed autologous bone-patellar tendon-bone transplantation to replace damaged ACLs in 20 athletes who had sustained injury. Cytori Cell Therapy utilizing adipose derived regenerative cells prepared by the Celution System from a patient’s own fat was used with the BPTB graft during the transplantation procedure. The cell preparation, injection into the graft and transplantation of the graft were all performed in the same surgical procedure. Dr. Cugat discussed the preliminary six month outcomes at the meeting. The procedure was feasible and not associated with safety issues above that seen with a standard small volume liposuction. All patients recovered without any complications. The results were compared to a historical control group of patients who had the same surgical procedure by the same surgical team but without other interventions. Overall, recovery from pain and ability to return to the field appeared to be accelerated as a result of the ADRC enriched BPTB transplant The patient questionnaires and serial MRI scans of the knees following cell therapy were consistent with accelerated healing of the graft.
08:02 EDTHFWAHeritage Financial declares 16c special dividend
Subscribe for More Information
08:02 EDTGMANGordmans Stores reports Q3 EPS (10c), consensus (10c)
Subscribe for More Information
08:02 EDTNVIVInvivo Therapeutics names fifth clinical site for neuro-spinal scoffold study
InVivo Therapeutics Holdings announced that the Oregon Health & Science University in Portland, OR is the fifth clinical site in the company’s ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury. OHSU is a nationally prominent research university and Oregon’s only public academic health center, seeing nearly one million patients every year. Ahmed Raslan, MD, an Assistant Professor of Neurological Surgery at OHSU, will be the study’s Principal Investigator at that site. On October 15, InVivo announced enrollment of its first patient at Barrow Neurological Institute in Phoenix, Arizona. Mark Perrin, InVivo’s CEO, said, “We continue to bring great centers into our study and are delighted to have Dr. Raslan and OHSU join us. OHSU and the other centers will be able to enroll the next subject following the three-month observation period for first patient.” This is the company’s first clinical study of its investigational degradable polymer Neuro-Spinal Scaffold. The IDE pilot study has been approved by the U.S. FDA and is intended to capture preliminary safety and effectiveness data of the Neuro-Spinal Scaffold in five subjects with acute thoracic spinal cord injury. InVivo then expects to conduct a pivotal study to obtain FDA approval to commence commercialization under a Humanitarian Device Exemption.
08:01 EDTCNCCentene jv selected to provide correctional healthcare In Vermont
Subscribe for More Information
08:01 EDTUGI, CBTUGI Corporation unit commences service on Marcellus shale projects
Subscribe for More Information
08:01 EDTPRXLPAREXEL revenue guidance looks 'aggressive,' says Jefferies
Jefferies views PAREXEL's 2015 revenue guidance as "aggressive" saying the company's backlog conversion must accelerate faster than 2014 levels just to hit the low end of the outlook. The firm keeps a Hold rating on the stock with a $57 price target.
07:57 EDTMPWMedical Properties Trust management to meet with Deutsche Bank
Subscribe for More Information
07:56 EDTHSBCHSBC's Swiss unit charged with money-laundering in Paris, AFP reports
Subscribe for More Information
07:56 EDTINTCIntel analyst day mixed, says FBR Capital
FBR Capital views Intel's analyst day as mixed since the company's gross margin and PC guidance came in below its expectations while it also announced a dividend increase and better than expected capex outlook. FBR raised its price target for Intel shares to $40 from $36 saying the cash return story is likely to temp income investors. It keeps an Outperform rating on the stock.
07:55 EDTWWWWolverine World Wide upgraded to Buy from Neutral at DA Davidson
Subscribe for More Information
07:54 EDTCSXCSX likely to deliver earnings growth above expectations, says UBS
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | all day >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use